A5103276749- Pharmacogenetics and Drug Metabolism
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Diabetes Treatment and Management
- Statistical Methods in Clinical Trials
- Computational Drug Discovery Methods
- Metabolism, Diabetes, and Cancer
Novartis (United States)
2024-2025
Texas A&M University
2022
Ono Pharmaceutical (United States)
2022
TPS617 Background: The phase 3 NATALEE trial met its primary endpoint with significant invasive disease–free survival benefit RIB + ET vs alone in a broad pt population stage II/III HR+/HER2− EBC, sustained additional follow-up at 44.2 months (hazard ratio, 0.715). Adjuvant WIDER will evaluate an EBC that reflects pts seen clinical practice as it has wider eligibility criteria, including focus on enrolling minority underrepresented NATALEE. Given the unmet need Stage results of this...
Abstract Purpose Alpelisib plus fulvestrant demonstrated a significant progression-free survival benefit versus in patients with PIK3CA- mutated HR+ /HER2− advanced breast cancer (ABC) (SOLAR-1). Hyperglycemia, an on-target adverse effect of PI3Kα inhibition, can lead to dose modifications, potentially impacting alpelisib efficacy. We report data from preclinical models and two clinical trials (SOLAR-1 BYLieve) on Sodium glucose cotransporter 2 inhibitor (SGLT2i) use improve...